Illumina (ILMN) to Release Quarterly Earnings on Thursday

Illumina (NASDAQ:ILMN) is expected to be issuing its Q1 2026 results after the market closes on Thursday, April 30th. Analysts expect the company to announce earnings of $1.06 per share and revenue of $1.0728 billion for the quarter. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, April 30, 2026 at 4:30 PM ET.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, beating analysts’ consensus estimates of $1.26 by $0.09. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.10 billion. Illumina had a net margin of 19.57% and a return on equity of 31.04%. Illumina’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period last year, the company posted $0.95 EPS. On average, analysts expect Illumina to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Illumina Trading Down 1.1%

Shares of Illumina stock opened at $130.50 on Thursday. The firm has a market capitalization of $19.82 billion, a PE ratio of 23.94, a P/E/G ratio of 2.53 and a beta of 1.49. Illumina has a twelve month low of $73.86 and a twelve month high of $155.53. The firm’s 50-day moving average price is $124.66 and its 200 day moving average price is $125.43. The company has a current ratio of 2.08, a quick ratio of 1.72 and a debt-to-equity ratio of 0.55.

Insider Activity

In other news, SVP Patricia Leckman sold 2,370 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the sale, the senior vice president directly owned 16,321 shares in the company, valued at $1,896,173.78. This represents a 12.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Illumina

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Toronto Dominion Bank increased its holdings in shares of Illumina by 0.3% in the fourth quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock valued at $4,407,000 after purchasing an additional 92 shares during the last quarter. Panagora Asset Management Inc. increased its holdings in shares of Illumina by 3.9% in the fourth quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock valued at $333,000 after purchasing an additional 96 shares during the last quarter. Parallel Advisors LLC increased its holdings in shares of Illumina by 4.7% in the third quarter. Parallel Advisors LLC now owns 2,834 shares of the life sciences company’s stock valued at $269,000 after purchasing an additional 128 shares during the last quarter. Zacks Investment Management increased its holdings in shares of Illumina by 0.6% in the third quarter. Zacks Investment Management now owns 24,655 shares of the life sciences company’s stock valued at $2,342,000 after purchasing an additional 143 shares during the last quarter. Finally, UMB Bank n.a. increased its holdings in shares of Illumina by 8.8% in the fourth quarter. UMB Bank n.a. now owns 1,943 shares of the life sciences company’s stock valued at $255,000 after purchasing an additional 157 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. UBS Group reaffirmed a “neutral” rating and issued a $135.00 price target on shares of Illumina in a research note on Friday, February 6th. TD Cowen reaffirmed a “hold” rating on shares of Illumina in a research note on Wednesday, January 7th. Guggenheim raised their price target on shares of Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Canaccord Genuity Group raised their price target on shares of Illumina from $130.00 to $150.00 and gave the company a “hold” rating in a research note on Monday, January 26th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Illumina in a research note on Monday, December 29th. Six research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Illumina has an average rating of “Hold” and an average price target of $129.69.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.